← Oncology Approval Tracker

FDA DECISION ·

Erbitux + Braftovi

cetuximab with encorafenib · ImClone / Array BioPharma

FDA approvalNew or expanded indicationColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with BRAF V600E-mutated metastatic colorectal cancer by an FDA-approved test after prior therapy.

LAMPGEN ANALYSIS

Why it matters

This approval adds the targeted combination to the cetuximab label after its prior approval on the encorafenib label.

What research teams should watch

Verify the BRAF substitution and prior treatment and use each product’s actual action date in the tracker.

PRIMARY RECORDS

Sources